Page last updated: 2024-11-02

pioglitazone and Cardiomyopathy, Restrictive

pioglitazone has been researched along with Cardiomyopathy, Restrictive in 1 studies

Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.

Cardiomyopathy, Restrictive: A form of CARDIAC MUSCLE disease in which the ventricular walls are excessively rigid, impeding ventricular filling. It is marked by reduced diastolic volume of either or both ventricles but normal or nearly normal systolic function. It may be idiopathic or associated with other diseases (ENDOMYOCARDIAL FIBROSIS or AMYLOIDOSIS) causing interstitial fibrosis.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Finsterer, J1
Stöllberger, C1

Other Studies

1 other study available for pioglitazone and Cardiomyopathy, Restrictive

ArticleYear
Pioglitazone-induced heart failure in a patient with restrictive cardiomyopathy and metabolic myopathy.
    Clinical research in cardiology : official journal of the German Cardiac Society, 2009, Volume: 98, Issue:4

    Topics: Cardiomyopathy, Restrictive; Diabetes Mellitus, Type 2; Heart Failure; Humans; Hypoglycemic Agents;

2009